Male breast carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm involving the male breast.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Male breast carcinoma
- Therapeutic area
- Oncology
- male breast carcinoma
- carcinoma of Male breast
- carcinoma of the Male breast
- Male breast cancer
- breast cancer in men
- breast cancer, male
- All therapeutic areas
- Oncology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0005628
- Parent condition
- MONDO:0004989
Related records
Broader conditions (16)
- Breast cancer
- Breast carcinoma
- Breast disorder
- Breast neoplasm
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Thoracic cancer
Trials (286)
- 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
- A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- A Study of PF-06873600 in People With Cancer
- Abraxane and Alimta in Advanced Solid Tumors
- Access to Genetic Testing in Underserved Patients With Cancer
- Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel
- Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
- Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
- AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
- Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
- Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
- Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
- Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
- Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
- Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
- Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Approved drugs (1)
- Elacestrant hydrochloride
Drugs in development (68)
- Abemaciclib Phase 2
- Aldesleukin Phase 2
- Alvocidib Phase 1
- Anastrozole Phase 2
- Azacitidine Phase 2
- Bavituximab Phase 1
- Becatecarin Phase 2
- Bevacizumab Phase 2
- Busulfan Phase 2
- Capecitabine Phase 2
- Carboplatin Phase 2
- Cediranib maleate Phase 2
- Cilengitide Phase 1
- Cixutumumab Phase 1
- Cyclophosphamide Phase 2
- Degarelix Phase 2
- Denileukin diftitox Phase 1
- Dinaciclib Phase 1
- Docetaxel Phase 1
- Doconexent Phase 2
Other linked drugs (1)
- Testosterone